



SUPPL. TABLE 1


								Compound Selectivity for Inhibition of NF-κB Activation Pathways ^b					
#	CID	*	R ₁	R ₂	R ₃	Y	n	NOD1 IC ₅₀ (uM) ^a	NOD2 IC ₅₀ (uM) ^a	TNF-α IC ₅₀ (uM) ^a	γ-tri-DAP NOD1 IC ₅₀ (uM)	PMA/Ionomycin ^b %act @ (0.25-25uM)	Doxorubicin DNA damage ^b %act @ (0.25-25uM)
1	1088438	P	H	H	Me	NH ₂	7	0.56±0.04	>20	>20	n.d. [§]	n.d.	n.d.
		S					6	0.71±0.15	>20	>20	0.97	0	0
2	1088439	P	H	H	Cl	NH ₂	2	0.48±0.14	>20	>20	n.d.	n.d.	n.d.
		S					2	0.09±0.01	>20	>20	1.08	0	0
3	44229066	S	H	H	OMe	NH ₂	4	2.7±0.69	>20	>20	2.48	0	0
4	3025920	S	H	H	H	NH ₂	4	2.2±0.21	>20	>20	5.24	0	0
5	746711	P	H	H	Me	H	2	6.3±0.81	>20	>20	9.66	0	0
6	3025945	S	H	H	NO ₂	NH ₂	6	14±1.8	>20	>20	>25	0	0
7	44229067	S	Me	Me	Me	NH ₂	4	>20	>20	>20	>25	0	0

* S = Synthesized P = Purchased
[§] n.d.=Not determined
^a Potency (uM) mean ± S.E.M., (n = replicates)
^b For the NF-κB Pathway specificity assays all compounds were tested at 0.25, 1.0, 2.5, 5.0, 10 & 25 uM



SUPPL. FIG.1




SUPPL. FIG.2




SUPPL. FIG.3




SUPPL. FIG.4




SUPPL. FIG.5







SUPPL. FIG.6




SUPPL. FIG.7




SUPPL. FIG.8




SUPPL. FIG.9



SUPPL. FIG.10



SUPPL. FIG.11



SUPPL. FIG.12

